Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Roche Acquires Majority Interest in WuXi-Invested Foundation Medicine

publication date: Jan 12, 2015
Roche will invest more than $1 billion to obtain a 56% stake in Foundation Medicine, a Boston company that offers a ground-breaking genomic test of cancer tumors. The FoundationOne® assay tests 343 regions of a tumor's genome to discover mutations and identify the best therapeutic option. WuXi PharmaTech's investment arm participated in Foundation's Series B round in 2012, and it partners with Foundation to provide the test in China. Roche's acquisition of Foundation provides WuXi with an early exit of its investment.  More details....

Stock Symbols: (SIX: ROG) (NSDQ: FMI) (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital